Affordable PD-1 From China? CStone Going Global With EQRx Onboard
'Made In China' IO To The World
Executive Summary
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
You may also be interested in...
EQRx Confronts US Drug Development Realities, Shifts Pricing Approach
Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.
EQRx Confronts US Drug Development Realities, Shifts Pricing Approach
Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.
Pfizer, CStone Score China's Seventh Immuno-Oncology Approval
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.